Stereotactic Ablative Radiotherapy May Be Feasible for Non-Small Cell Lung Cancer
the Cancer Therapy Advisor take:
Stereotactic ablative radiotherapy (SABR) could be an option for treating patients with operable stage I non-small cell lung cancer (NSCLC), a recent study published online first in the journal The Lancet Oncology has shown.
For the study, researchers conducted a pooled analysis of the STARS and ROSEL studies, which closed early due to slow accrual. In the intention-to-treat population, 58 patients with clinical T1-2a, N0M0, operable NSCLC were enrolled and randomly assigned 1:1 to SABR or lobectomy with mediastinal lymph node dissection or sampling.
Results showed that estimated overall survival at 3 years was 95% (95% CI: 85-100) in the SABR group versus 79% (95% CI: 64-97) in the lobectomy group (HR = 0.14; 95% CI: 0.017-1.190; log-rank P = 0.037). Researchers found that recurrence-free survival at 3 years was 86% (95% CI: 74-100) and 80% (95% CI: 65-97) in the SABR and surgery groups, respectively (HR = 0.69; 95% CI: 0.21-2.29; log-rank P = 0.54).
The researchers note that because of the small patient sample size and median follow-up of only 40.2 months in the SABR group and 35.4 months in the surgery group, additional randomized studies comparing the two in patients with operable NSCLC are needed.
Stereotactic ablative radiotherapy could be an option for treating patients with operable stage I NSCLC.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Considerations for Relapsed Myeloma Should Match Patient, Disease, and Therapy
- Triclosan and Cancer Risk: Is There a Link?
- Drugs Approved Under the Breakthrough Therapy Pathway Lack Basic Features of High-Quality Trials
- Combined Modality Therapy May Be More Effective Than Radiotherapy Alone in Follicular Lymphoma
- Chemotherapy May Improve Survival Outcomes in High-Risk Soft-Tissue Sarcoma